Royalty Pharma
- Market cap
- 25.27B
- P/E (TTM)i
- 30.52
- P/Bi
- 3.70
- EPSi
- 1.78
- Div yieldi
- 1.60%
- 52W posi
- 74%
Anonymous reader poll. Unscientific, not investment advice.
Royalty Pharma shares were changing hands at 56.76, up 0.57% on the day. Its market capitalisation is about 25.27B, the #759 most valuable US-listed company we track. Valuation-wise, the P/E sits at 31.38, 24% below the five-year average of 41.54. The stock also carries a trailing dividend yield of 1.60%. Across 7 analysts the consensus rating is Buy, with an average price target of 65.71 (+16%). The shares sit 74% of the way up their 52-week range of 34.56 to 64.38.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 14% of the universe, above its 200-day average.
- Signal has read BUY for 6 months.
- Recent price momentum is +29.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 2.6% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation C-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 30.5x | Better than 27% |
| Forward P/E | 15.9x | Better than 57% |
| Price / Sales | 10.2x | Better than 12% |
| P/E vs own 5-yr range | 67th pctl | Better than 42% |
Growth B
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 2.1% | Better than 28% |
| Net income CAGR (3Y) | 162.1% | Better than 98% |
| Free cash flow CAGR (3Y) | 5.1% | Better than 42% |
Profitability A-
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | 65.6% | Better than 99% |
| Net margin | 32.4% | Better than 92% |
| Return on equity | 11.5% | Better than 44% |
| Return on invested capital | 7.0% | Better than 40% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -1.6% | Better than 51% |
| 6-month return | 21.9% | Better than 73% |
| 12-month return (ex latest month) | 80.5% | Better than 91% |
| Distance below 52-week high | 12.0% | Better than 69% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.4x | Better than 75% |
| Debt to assets | 45.6% | Better than 31% |
| Interest coverage | 5.3x | Better than 43% |
| Free cash flow / net income | 323.0% | Better than 91% |
Analyst View B
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 80% |
| Upside to average target | 16.0% | Better than 29% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 56.44
- Open
- 56.61
- Day range
- 56.41 - 57.16
- Avg price
- 56.76
- Volume
- 3.67M
- Turnover
- 208.38M
- Turnover ratei
- 0.88%
- Volume ratioi
- 1.06
- Amplitudei
- 1.33%
- 52-week rangei
- 34.56 - 64.38
Valuation
- P/Ei
- 31.89
- P/E (TTM)i
- 30.52
- P/Bi
- 3.70
- EPSi
- 1.78
- Book value / shi
- 15.35
- Net profit
- 792.59M
- Net assets
- 6.83B
Share structure
- Market cap
- 25.27B
- Float capi
- 23.59B
- Shares out
- 445.28M
- Float sharesi
- 415.52M
Dividend & listing
- Div yield (TTM)i
- 1.60%
- Dividend (TTM)
- 0.91
- Listing date
- 2020-06-16
11.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-57.82M net over the window
Short interest
- Shares short
- 11.65M
- % of floati
- 2.62%
- Days to coveri
- 3.25
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Royalty Pharma (RPRX)?
Royalty Pharma last traded at 56.76. The quote on this page refreshes every few seconds while US markets are open.
What is Royalty Pharma's market cap?
About 25.27B.
What is the P/E ratio of Royalty Pharma?
The trailing twelve-month P/E is 30.52, below its own 5-year average of 41.54 — toward the top of its historical range (66.80% percentile). See the Valuation tab for the full history.
Does Royalty Pharma pay a dividend?
Yes. The trailing dividend yield is 1.60%. The 2025 payout was up 4.8% from 2024. See the Dividends tab for the full payment history.
Is Royalty Pharma a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 65.71, which implies 15.8% upside from the current price. This is not investment advice.
What is Royalty Pharma's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Royalty Pharma a B (Buy). Twelve-month momentum in the top 14% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 07:37:27 · For reference only, not investment advice and not tailored to your situation.